Search

Your search keyword '"Steg, P.-G."' showing total 483 results
Start Over Author "Steg, P.-G."
483 results on '"Steg, P.-G."'

1. P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention

Author

Capodanno, Davide, Baber, Usman, Bhatt, Deepak L., Collet, Jean-Philippe, Dangas, George, Franchi, Francesco, Gibson, C. Michael, Gwon, Hyeon-Cheol, Kastrati, Adnan, Kimura, Takeshi, Lemos, Pedro A., Lopes, Renato D., Mehran, Roxana, O’Donoghue, Michelle L., Rao, Sunil V., Rollini, Fabiana, Serruys, Patrick W., Steg, Philippe G., Storey, Robert F., Valgimigli, Marco, Vranckx, Pascal, Watanabe, Hirotoshi, Windecker, Stephan, and Angiolillo, Dominick J.

Published
2022
Full Text
View/download PDF

2. Two of a kind: mass and molar immunoassay-based lipoprotein (a) concentrations are similarly prognostic for MACE risk and predictive of alirocumab benefit in ODYSSEY OUTCOMES

Author

Szarek, M, primary, Steg, P G, additional, Jukema, J W, additional, Reijders, E, additional, Schwertfeger, M, additional, Bhatt, D, additional, Bittner, V, additional, Diaz, R, additional, Fazio, S, additional, Garon, G, additional, Goodman, S G, additional, Harrington, R A, additional, White, H, additional, Cobbaert, C, additional, and Schwartz, G G, additional

Published
2023
Full Text
View/download PDF

3. Eicosapentaenoic acid, arachidonic acid, and triglyceride levels mediate most of the benefit of icosapent ethyl in REDUCE-IT

Author

Szarek, M, primary, Bhatt, D, additional, Miller, M, additional, Steg, P G, additional, Brinton, E A, additional, Jacobson, T A, additional, Tardif, J C, additional, Ballantyne, C M, additional, Ketchum, S B, additional, Pineda, A L, additional, Dunbar, R L, additional, Siri-Tarino, P W, additional, and Mason, R P, additional

Published
2023
Full Text
View/download PDF

5. Impact of transfusion on platelet aggregation and biomarkers in myocardial infarction patients with anemia: an ancillary study of the randomized REALITY trial

Author

Silvain, J, primary, Lattuca, B, additional, Puymirat, E, additional, Ducrocq, G, additional, Dillinger, J G, additional, Lhermusier, T, additional, Cachanado, M, additional, Drouet, E, additional, Abergel, H, additional, Danchin, N, additional, Montalescot, G, additional, Simon, T, additional, and Steg, P G, additional

Published
2023
Full Text
View/download PDF

9. Design of knowledge-based mechanistic model of atherosclerotic cardiovascular disease for in silico trials

Author

Angoulvant, D, primary, Amarenco, P, additional, Bastien, A, additional, Bechet, E, additional, Boccara, F, additional, Boissel, J P, additional, Cariou, B, additional, Courcelles, E, additional, Granjeon-Noriot, S, additional, Mahe, G, additional, Peyronnet, E, additional, Portal, L, additional, Porte, S, additional, Wang, Y, additional, and Steg, P G, additional

Published
2023
Full Text
View/download PDF

10. Effect of a restrictive vs. liberal blood transfusion strategy among patients with acute myocardial infarction and anemia according to heart failure. A subgroup analysis of the REALITY trial

Author

Ducrocq, G, primary, Cachanado, M, additional, Simon, T, additional, Puymirat, E, additional, Lemesle, G, additional, Lattuca, B, additional, Ariza-Sole, A, additional, Silvain, J, additional, Ferrari, E, additional, Gonzalez Juanatey, J R, additional, Martinez Selles, M, additional, Calvo, G, additional, and Steg, P G, additional

Published
2023
Full Text
View/download PDF

13. Prognostic importance of NT-proBNP following high-risk myocardial infarction in the PARADISE-MI Trial

Author

Jering, K, primary, Claggett, B, additional, Pfeffer, M A, additional, Granger, C, additional, Kober, L, additional, Lewis, E F, additional, Maggioni, A P, additional, Mann, D L, additional, McMurray, J J V, additional, Prescott, M F, additional, Rouleau, J L, additional, Solomon, S D, additional, Steg, P G, additional, Von Lewinski, D, additional, and Braunwald, E, additional

Published
2022
Full Text
View/download PDF

17. Longer-term safety of alirocumab with 24,610 patient-years of placebo-controlled observation: further insights from the ODYSSEY OUTCOMES trial

Author

Goodman, S, primary, Steg, P G, additional, Szarek, M, additional, Bhatt, D L, additional, Bittner, V A, additional, Diaz, R, additional, Harrington, R A, additional, Jukema, J W, additional, White, H D, additional, Zeiher, A M, additional, Manvelian, G, additional, Poulouin, Y, additional, Scemama, M, additional, Stipek, W, additional, and Schwartz, G G, additional

Published
2022
Full Text
View/download PDF

25. Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial

Author

Pfeffer, M, Claggett, B, Lewis, E, Granger, C, Kober, L, Maggioni, A, Mann, D, Mcmurray, J, Rouleau, J, Solomon, S, Steg, P, Berwanger, O, Cikes, M, De Pasquale, C, Fernandez, A, Filippatos, G, Jering, K, Landmesser, U, Menon, V, Merkely, B, Petrie, M, Petrov, I, Schou, M, Senni, M, Sim, D, van der Meer, P, Lefkowitz, M, Zhou, Y, Wang, Y, Braunwald, E, Pfeffer M. A., Claggett B., Lewis E. F., Granger C. B., Kober L., Maggioni A. P., Mann D. L., McMurray J. J. V., Rouleau J. -L., Solomon S. D., Steg P. G., Berwanger O., Cikes M., De Pasquale C. G., Fernandez A., Filippatos G., Jering K., Landmesser U., Menon V., Merkely B., Petrie M. C., Petrov I., Schou M., Senni M., Sim D., van der Meer P., Lefkowitz M., Zhou Y., Wang Y., Braunwald E., Pfeffer, M, Claggett, B, Lewis, E, Granger, C, Kober, L, Maggioni, A, Mann, D, Mcmurray, J, Rouleau, J, Solomon, S, Steg, P, Berwanger, O, Cikes, M, De Pasquale, C, Fernandez, A, Filippatos, G, Jering, K, Landmesser, U, Menon, V, Merkely, B, Petrie, M, Petrov, I, Schou, M, Senni, M, Sim, D, van der Meer, P, Lefkowitz, M, Zhou, Y, Wang, Y, Braunwald, E, Pfeffer M. A., Claggett B., Lewis E. F., Granger C. B., Kober L., Maggioni A. P., Mann D. L., McMurray J. J. V., Rouleau J. -L., Solomon S. D., Steg P. G., Berwanger O., Cikes M., De Pasquale C. G., Fernandez A., Filippatos G., Jering K., Landmesser U., Menon V., Merkely B., Petrie M. C., Petrov I., Schou M., Senni M., Sim D., van der Meer P., Lefkowitz M., Zhou Y., Wang Y., and Braunwald E.

Published
2022

27. Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids-DOTT trial): pilot/feasibility phase findings

Author

GOLDENBERG, N. A., ABSHIRE, T., BLATCHFORD, P. J., FENTON, L. Z., HALPERIN, J. L., HIATT, W. R., KESSLER, C. M., KITTELSON, J. M., MANCO-JOHNSON, M. J., SPYROPOULOS, A. C., STEG, P. G., STENCE, N. V., TURPIE, A. G. G., SCHULMAN, S., PUNZALAN, R., WANG, M., JAFFRAY, J., YOUNG, G., RAJPURKAR, M., CARPENTER, S., DIAB, Y., VERDUN, N., TARANGO, C., ACHARYA, S., TORRES, M., KUCINE, N., MITCHELL, B., SHAH, N., THORNBURG, C., TAKEMOTO, C., KULKARNI, R., O'BRIEN, S., HALEY, K., RECHT, M., KNOLL, C., GEDDIS, A., AHUJA, S., SIMPSON, M., SRIVATHS, L., JOURNEYCAKE, J., and ZIA, A.

Published
2015
Full Text
View/download PDF

32. Angiotensin receptor–neprilysin inhibition in acute myocardial infarction

Author

Pfeffer, M, Claggett, B, Lewis, E, Granger, C, Kober, L, Maggioni, A, Mann, D, Mcmurray, J, Rouleau, J, Solomon, S, Steg, P, Berwanger, O, Cikes, M, De Pasquale, C, East, C, Fernandez, A, Jering, K, Landmesser, U, Mehran, R, Merkely, B, Mody, F, Petrie, M, Petrov, I, Schou, M, Senni, M, Sim, D, van der Meer, P, Lefkowitz, M, Zhou, Y, Gong, J, Braunwald, E, Pfeffer M. A., Claggett B., Lewis E. F., Granger C. B., Kober L., Maggioni A. P., Mann D. L., McMurray J. J. V., Rouleau J. -L., Solomon S. D., Steg P. G., Berwanger O., Cikes M., De Pasquale C. G., East C., Fernandez A., Jering K., Landmesser U., Mehran R., Merkely B., Mody F. V., Petrie M. C., Petrov I., Schou M., Senni M., Sim D., van der Meer P., Lefkowitz M., Zhou Y., Gong J., Braunwald E., Pfeffer, M, Claggett, B, Lewis, E, Granger, C, Kober, L, Maggioni, A, Mann, D, Mcmurray, J, Rouleau, J, Solomon, S, Steg, P, Berwanger, O, Cikes, M, De Pasquale, C, East, C, Fernandez, A, Jering, K, Landmesser, U, Mehran, R, Merkely, B, Mody, F, Petrie, M, Petrov, I, Schou, M, Senni, M, Sim, D, van der Meer, P, Lefkowitz, M, Zhou, Y, Gong, J, Braunwald, E, Pfeffer M. A., Claggett B., Lewis E. F., Granger C. B., Kober L., Maggioni A. P., Mann D. L., McMurray J. J. V., Rouleau J. -L., Solomon S. D., Steg P. G., Berwanger O., Cikes M., De Pasquale C. G., East C., Fernandez A., Jering K., Landmesser U., Mehran R., Merkely B., Mody F. V., Petrie M. C., Petrov I., Schou M., Senni M., Sim D., van der Meer P., Lefkowitz M., Zhou Y., Gong J., and Braunwald E.

Abstract

BACKGROUND In patients with symptomatic heart failure, sacubitril–valsartan has been found to reduce the risk of hospitalization and death from cardiovascular causes more effectively than an angiotensin-converting–enzyme inhibitor. Trials comparing the effects of these drugs in patients with acute myocardial infarction have been lacking. METHODS We randomly assigned patients with myocardial infarction complicated by a reduced left ventricular ejection fraction, pulmonary congestion, or both to receive either sacubitril–valsartan (97 mg of sacubitril and 103 mg of valsartan twice daily) or ramipril (5 mg twice daily) in addition to recommended therapy. The primary outcome was death from cardiovascular causes or incident heart failure (outpatient symptomatic heart failure or heart failure leading to hospitalization), whichever occurred first. RESULTS A total of 5661 patients underwent randomization; 2830 were assigned to receive sacubitril–valsartan and 2831 to receive ramipril. Over a median of 22 months, a primary-outcome event occurred in 338 patients (11.9%) in the sacubitril–valsartan group and in 373 patients (13.2%) in the ramipril group (hazard ratio, 0.90; 95% confidence interval [CI], 0.78 to 1.04; P=0.17). Death from cardiovascular causes or hospitalization for heart failure occurred in 308 patients (10.9%) in the sacubitril–valsartan group and in 335 patients (11.8%) in the ramipril group (hazard ratio, 0.91; 95% CI, 0.78 to 1.07); death from cardiovascular causes in 168 (5.9%) and 191 (6.7%), respectively (hazard ratio, 0.87; 95% CI, 0.71 to 1.08); and death from any cause in 213 (7.5%) and 242 (8.5%), respectively (hazard ratio, 0.88; 95% CI, 0.73 to 1.05). Treatment was discontinued because of an adverse event in 357 patients (12.6%) in the sacubitril–valsartan group and 379 patients (13.4%) in the ramipril group. CONCLUSIONS Sacubitril–valsartan was not associated with a significantly lower incidence of death from cardiovascular causes or incident hear

Published
2021

36. Impact of preoperative maintenance or interruption of aspirin on thrombotic and bleeding events after elective non-cardiac surgery: the multicentre, randomized, blinded, placebo-controlled, STRATAGEM trial†

Author

Mantz, J., Samama, C. M., Tubach, F., Devereaux, P. J., Collet, J.-P., Albaladejo, P., Cholley, B., Nizard, R., Barré, J., Piriou, V., Poirier, N., Mignon, A., Schlumberger, S., Longrois, D., Aubrun, F., Farèse, M. E., Ravaud, P., and Steg, P. G.

Published
2011
Full Text
View/download PDF

45. P2Y12inhibitor monotherapy in patients undergoing percutaneous coronary intervention

Author

Capodanno, Davide, Baber, Usman, Bhatt, Deepak L., Collet, Jean-Philippe, Dangas, George, Franchi, Francesco, Gibson, C. Michael, Gwon, Hyeon-Cheol, Kastrati, Adnan, Kimura, Takeshi, Lemos, Pedro A., Lopes, Renato D., Mehran, Roxana, O’Donoghue, Michelle L., Rao, Sunil V., Rollini, Fabiana, Serruys, Patrick W., Steg, Philippe G., Storey, Robert F., Valgimigli, Marco, Vranckx, Pascal, Watanabe, Hirotoshi, Windecker, Stephan, and Angiolillo, Dominick J.

Abstract

For 20 years, dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and a platelet P2Y12receptor inhibitor, has been the gold standard of antithrombotic pharmacology after percutaneous coronary intervention (PCI). In the past 5 years, several investigations have challenged this paradigm by testing the efficacy and safety of P2Y12inhibitor monotherapy (that is, without aspirin) following a short course of DAPT. Collectively, these studies suggested a reduction in the risk of major bleeding and no significant increase in thrombotic or ischaemic events compared with guideline-recommended DAPT. Current recommendations are evolving to inform clinical practice on the ideal candidates for P2Y12inhibitor monotherapy after PCI. Generalizing the results of studies of P2Y12inhibitor monotherapy requires a thorough understanding of their design, populations, interventions, comparators and results. In this Review, we provide an up-to-date overview on the use of P2Y12inhibitor monotherapy after PCI, including supporting pharmacodynamic and clinical evidence, practical recommendations and future directions.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results